The nuclear medicine market is expected to reach USD 13.8 billion
by 2024, according to a new report by Grand View Research, Inc. The burden of
chronic diseases such as cancer and cardiac disorders is on rise. Nuclear
medicine products are widely used for diagnosis as well as treatment of
cancerous and cardiovascular disease.
The increasing prevalence of these
disorders poses direct impact on usage of radiopharmaceutical market. For
instance, as per the data published by the World Health Organization (WHO), the
incidences of cancer are anticipated to increase by 70.0% which is further
anticipated to drive the demand for radiopharmaceuticals.
The diagnostics when combined with nuclear
medicine improve on accuracy. The accuracy in the diagnosis has a direct impact
on the decision-making and treatment monitoring process. Adoption of PET as a
diagnostic tool is rapidly increasing since it has high accuracy over other
diagnostic techniques.
Full research report on Nuclear Medicine Market analysis: http://www.grandviewresearch.com/industry-analysis/nuclear-medicines-market
Further key findings from the study suggest:
·
The product segments of nuclear medicine
are divided into diagnostic and therapeutic. Diagnostic products held
commanding share in 2015, this can be attributed to the advancements in
scanning technologies.
·
Therapeutic products such as Alpha
Emitters, Beta Emitters and Brachytherapy are anticipated to exhibit lucrative
growth.
·
The key diagnostic application areas of
nuclear medicine formed the largest market in 2015. These applications are in
cardiology, neurology, oncology, and thyroid.
·
North America owing to well-planned
policies, reimbursement structure, high healthcare spending and increasing
awareness dominated global nuclear medicine market in 2015.
·
Asia Pacific is expected to witness
lucrative growth in coming eight years. Increasing per capita income and reform
in policies is favoring market players in terms of ease of doing business.
·
The players in the nuclear medicine
industry include Eckert & Ziegler Group, Mallinckrodt Pharmaceuticals, GE
Healthcare, Jubilant Life Sciences, Bracco Imaging S.p.A, Nordion, Inc.
View more reports of this category by Grand View Research
at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global nuclear medicine market on the basis of product and region:
Global Product Outlook (Revenue, USD Million, 2013 -
2024)
·
Diagnostics
o SPECT
o TC-99m
o TL-201
o GA-67
o I-123
o Others
o PET
o F-18
o RB-82
o Others
·
Therapeutics
o Alpha Emitters
o RA-223
o Beta Emitters
o I-131
o Y-90
o SM-153
o Re-186
o Lu-117
o Others
o Brachytherapy
o Cesium-131
o Iodine-125
o Palladium-103
o Iridium-192
o Others
Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o UK
o Germany
·
Asia Pacific
o Japan
o China
·
Latin America
o Brazil
o Mexico
·
MEA
o South Africa
View press
release of this research report by Grand View Research: https://www.grandviewresearch.com/press-release/global-nuclear-medicines-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
